Cargando…

Subacute toxicity evaluations of LPM3480392 in rats, a full µ-opioid receptor biased agonist

Opiates produce analgesia via G-protein signaling, and adverse effects, such as respiratory depression and decreased bowel motility, by β-arrestin pathway. Oliceridine, a G protein-biased MOR agonist, only presents modest safety advantages as compared to other opiates in clinical trials, possibly du...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Liang, Li, Chunmei, Jiang, Wanglin, Yang, Yifei, Wang, Wenyan, Zhu, Haibo, Hu, Zhengping, Li, Ning, Cen, Xiaobo, Wang, Hongbo, Tian, Jingwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10436550/
https://www.ncbi.nlm.nih.gov/pubmed/37601058
http://dx.doi.org/10.3389/fphar.2023.1218380
_version_ 1785092356273340416
author Ye, Liang
Li, Chunmei
Jiang, Wanglin
Yang, Yifei
Wang, Wenyan
Zhu, Haibo
Hu, Zhengping
Li, Ning
Cen, Xiaobo
Wang, Hongbo
Tian, Jingwei
author_facet Ye, Liang
Li, Chunmei
Jiang, Wanglin
Yang, Yifei
Wang, Wenyan
Zhu, Haibo
Hu, Zhengping
Li, Ning
Cen, Xiaobo
Wang, Hongbo
Tian, Jingwei
author_sort Ye, Liang
collection PubMed
description Opiates produce analgesia via G-protein signaling, and adverse effects, such as respiratory depression and decreased bowel motility, by β-arrestin pathway. Oliceridine, a G protein-biased MOR agonist, only presents modest safety advantages as compared to other opiates in clinical trials, possibly due to its limited bias. Our previous study shown that LPM3480392, a full MOR biased agonist, is selective for the Gi pathway over the β-arrestin-2. In the present article, we evaluated the subacute toxicity of LPM3480392 in rats. The rats were administered with control article or LPM3480392 0.6, 1.2 or 2.4 mg/kg/day for 4 consecutive weeks followed by a 4-week recovery phase. Intravenous infusion was conducted at tail vein at 0.2, 0.4 or 0.8 mg/kg/day with a dosing volume of 10 mL/kg and 5 min/rat/dose, three times a day with an interval of approximately 4 h. The concomitant toxicokinetics study was conducted. Two unscheduled rats at 2.4 mg/kg/day died with no clear cause. For the scheduled necropsy, the major effects were associated with the MOR agonist-related pharmacodynamic properties of LPM3480392 (e.g., increased activity, increased muscle tone; decreased food consumption and body weight gain; and clinical chemistry changes related with decreased food consumption) in three LPM3480392 groups. In addition, LPM3480392 at 2.4 mg/kg/day also induced deep respiration and histopathology changes in testis and epididymis in sporadic individual rats. However, different from other opiates, LPM3480392 presents weak/no immunosuppression and the decreased adrenal gland weight, which may be due to LPM3480392’ full MOR bias. At the end of recovery phase, all findings were recovered to some extent or completely. In the toxicokinetics study, the dose-dependent elevation of drug exposure was observed, which partly explained the toxicity of high dose. In summary, LPM3480392 has exhibited good safety characteristics in this subacute toxicity study in rats.
format Online
Article
Text
id pubmed-10436550
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-104365502023-08-19 Subacute toxicity evaluations of LPM3480392 in rats, a full µ-opioid receptor biased agonist Ye, Liang Li, Chunmei Jiang, Wanglin Yang, Yifei Wang, Wenyan Zhu, Haibo Hu, Zhengping Li, Ning Cen, Xiaobo Wang, Hongbo Tian, Jingwei Front Pharmacol Pharmacology Opiates produce analgesia via G-protein signaling, and adverse effects, such as respiratory depression and decreased bowel motility, by β-arrestin pathway. Oliceridine, a G protein-biased MOR agonist, only presents modest safety advantages as compared to other opiates in clinical trials, possibly due to its limited bias. Our previous study shown that LPM3480392, a full MOR biased agonist, is selective for the Gi pathway over the β-arrestin-2. In the present article, we evaluated the subacute toxicity of LPM3480392 in rats. The rats were administered with control article or LPM3480392 0.6, 1.2 or 2.4 mg/kg/day for 4 consecutive weeks followed by a 4-week recovery phase. Intravenous infusion was conducted at tail vein at 0.2, 0.4 or 0.8 mg/kg/day with a dosing volume of 10 mL/kg and 5 min/rat/dose, three times a day with an interval of approximately 4 h. The concomitant toxicokinetics study was conducted. Two unscheduled rats at 2.4 mg/kg/day died with no clear cause. For the scheduled necropsy, the major effects were associated with the MOR agonist-related pharmacodynamic properties of LPM3480392 (e.g., increased activity, increased muscle tone; decreased food consumption and body weight gain; and clinical chemistry changes related with decreased food consumption) in three LPM3480392 groups. In addition, LPM3480392 at 2.4 mg/kg/day also induced deep respiration and histopathology changes in testis and epididymis in sporadic individual rats. However, different from other opiates, LPM3480392 presents weak/no immunosuppression and the decreased adrenal gland weight, which may be due to LPM3480392’ full MOR bias. At the end of recovery phase, all findings were recovered to some extent or completely. In the toxicokinetics study, the dose-dependent elevation of drug exposure was observed, which partly explained the toxicity of high dose. In summary, LPM3480392 has exhibited good safety characteristics in this subacute toxicity study in rats. Frontiers Media S.A. 2023-08-04 /pmc/articles/PMC10436550/ /pubmed/37601058 http://dx.doi.org/10.3389/fphar.2023.1218380 Text en Copyright © 2023 Ye, Li, Jiang, Yang, Wang, Zhu, Hu, Li, Cen, Wang and Tian. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Ye, Liang
Li, Chunmei
Jiang, Wanglin
Yang, Yifei
Wang, Wenyan
Zhu, Haibo
Hu, Zhengping
Li, Ning
Cen, Xiaobo
Wang, Hongbo
Tian, Jingwei
Subacute toxicity evaluations of LPM3480392 in rats, a full µ-opioid receptor biased agonist
title Subacute toxicity evaluations of LPM3480392 in rats, a full µ-opioid receptor biased agonist
title_full Subacute toxicity evaluations of LPM3480392 in rats, a full µ-opioid receptor biased agonist
title_fullStr Subacute toxicity evaluations of LPM3480392 in rats, a full µ-opioid receptor biased agonist
title_full_unstemmed Subacute toxicity evaluations of LPM3480392 in rats, a full µ-opioid receptor biased agonist
title_short Subacute toxicity evaluations of LPM3480392 in rats, a full µ-opioid receptor biased agonist
title_sort subacute toxicity evaluations of lpm3480392 in rats, a full µ-opioid receptor biased agonist
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10436550/
https://www.ncbi.nlm.nih.gov/pubmed/37601058
http://dx.doi.org/10.3389/fphar.2023.1218380
work_keys_str_mv AT yeliang subacutetoxicityevaluationsoflpm3480392inratsafullμopioidreceptorbiasedagonist
AT lichunmei subacutetoxicityevaluationsoflpm3480392inratsafullμopioidreceptorbiasedagonist
AT jiangwanglin subacutetoxicityevaluationsoflpm3480392inratsafullμopioidreceptorbiasedagonist
AT yangyifei subacutetoxicityevaluationsoflpm3480392inratsafullμopioidreceptorbiasedagonist
AT wangwenyan subacutetoxicityevaluationsoflpm3480392inratsafullμopioidreceptorbiasedagonist
AT zhuhaibo subacutetoxicityevaluationsoflpm3480392inratsafullμopioidreceptorbiasedagonist
AT huzhengping subacutetoxicityevaluationsoflpm3480392inratsafullμopioidreceptorbiasedagonist
AT lining subacutetoxicityevaluationsoflpm3480392inratsafullμopioidreceptorbiasedagonist
AT cenxiaobo subacutetoxicityevaluationsoflpm3480392inratsafullμopioidreceptorbiasedagonist
AT wanghongbo subacutetoxicityevaluationsoflpm3480392inratsafullμopioidreceptorbiasedagonist
AT tianjingwei subacutetoxicityevaluationsoflpm3480392inratsafullμopioidreceptorbiasedagonist